<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Development</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>TOI story creates buzz in RP as Kiora seals $301M deal</title>
      <description>
        <![CDATA[Kiora Pharmaceuticals Inc.’s development and commercialization deal with Théa Open Innovation (TOI), a sister company of Laboratoires Théa, for KIO-301 in degenerative retinal diseases “takes a bit of an industry-standard type of approach” in terms of structure, said CEO Brian Strem.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705206</guid>
      <pubDate>Thu, 01 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705206-toi-story-creates-buzz-in-rp-as-kiora-seals-301m-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-financial-charts.webp?t=1685051887" type="image/jpeg" medium="image" fileSize="207505">
        <media:title type="plain">Eye and financial charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Human organ atlas maps healthy and diseased tissues at the cellular level</title>
      <description>
        <![CDATA[The Hubmap consortium has released the atlas of three human organs, a cell-by-cell map based on overlaid images from microscopy and molecular data. Maps of the intestine, the kidney and the placenta, published in three simultaneous articles, have revealed the cellular morphology and architecture of these organs in healthy and diseased conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699161</guid>
      <pubDate>Thu, 20 Jul 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699161-human-organ-atlas-maps-healthy-and-diseased-tissues-at-the-cellular-level</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/HuBMAP-Intestine.webp?t=1689864164" type="image/jpeg" medium="image" fileSize="729192">
        <media:title type="plain">Cells of the human intestine</media:title>
        <media:description type="plain">Cells of the human intestine. Credit: Stanford Medicine/Snyder lab/Nolan lab/Greenleaf lab</media:description>
      </media:content>
    </item>
    <item>
      <title>New human embryonic models bring hope for insights, but also lots of brouhaha</title>
      <description>
        <![CDATA[The development of an embryo in its early stages involves a series of processes in which cells interact and organize to form tissues. In humans, these stages are studied with animal models, stem cells and cell aggregates that mimic natural development phases, or with human embryos, depending on their availability and a strict protocol. Now, in back-to-back papers published online in <em>Nature</em>, scientists from Yale University and the University of Cambridge have two new embryonic models formed from human stem cells to study development after embryo implantation in the uterus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/698430</guid>
      <pubDate>Wed, 28 Jun 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/698430-new-human-embryonic-models-bring-hope-for-insights-but-also-lots-of-brouhaha</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Cambridge-embryo-model.webp?t=1687964404" type="image/png" medium="image" fileSize="696184">
        <media:title type="plain">Day 4 embryoid showing an inner epiblast-like domain that has apico-basal polarity</media:title>
        <media:description type="plain">Day 4 embryoid showing an inner epiblast-like domain (magenta) that has apico-basal polarity (yellow apical, blue basal) similar to the epiblast of the human embryo just after implantation. Credit: University of Cambridge.</media:description>
      </media:content>
    </item>
    <item>
      <title>Scant backlash from NASH crash as Genfit scores $539M-plus Ipsen deal in PBC</title>
      <description>
        <![CDATA[Genfit SA’s global development and commercialization deal with Ipsen Pharma SA for phase III-stage elafibranor in primary biliary cholangitis (PBC) – plus a separate arrangement for rights to an asset earlier in development from Genoscience Pharma SA – represent “the logical next steps in the implementation of a strategy that we outlined to you about 18 months ago,” Genfit CEO Pascal Prigent said during a conference call with investors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514377</guid>
      <pubDate>Fri, 17 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514377-scant-backlash-from-nash-crash-as-genfit-scores-539m-plus-ipsen-deal-in-pbc</link>
    </item>
    <item>
      <title>Takeda secures ex-U.S. rights to JCR Pharma’s Hunter syndrome treatment</title>
      <description>
        <![CDATA[Takeda Pharmaceutical Co. Ltd. and JCR Pharmaceuticals Co. Ltd. have negotiated a geographically-focused licensing deal to develop and commercialize JR-141 (pabinafusp alfa), a potential therapy for mucopolysaccharidosis type II, also known as Hunter syndrome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512080</guid>
      <pubDate>Tue, 05 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512080-takeda-secures-ex-us-rights-to-jcr-pharmas-hunter-syndrome-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWA-source/2021/JCR-Research-10-5.webp?t=1633466580" type="image/png" medium="image" fileSize="1253350">
        <media:title type="plain">JCR-Research-10-5</media:title>
        <media:description type="plain">Credit: JCR Pharmaceuticals</media:description>
      </media:content>
    </item>
    <item>
      <title>Sumitomo’s Sunovion and Otsuka sign $890M worldwide development collaboration deal for four neuropsychiatric compounds</title>
      <description>
        <![CDATA[Sumitomo Dainippon Pharma Co. Ltd., its U.S.-based subsidiary Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Co. Ltd. have inked a global collaboration agreement to jointly advance four new compounds for serious neuropsychiatric conditions. Sunovion granted Otsuka rights to collaboratively develop and commercialize the four compounds worldwide. In return, Sunovion will receive an up-front payment of $270 million and up to $620 million in development milestone payments for the agents, with the potential for more depending on additional indications. It could also receive sales milestones from Otsuka.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512069</guid>
      <pubDate>Tue, 05 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512069-sumitomos-sunovion-and-otsuka-sign-890m-worldwide-development-collaboration-deal-for-four-neuropsychiatric-compounds</link>
    </item>
    <item>
      <title>Ascentage co-develops Bcl-2 and BTK combination therapy for SLL/CLL with Astrazeneca</title>
      <description>
        <![CDATA[BEIJING – Suzhou, China-based Ascentage Pharma Group Inc. said on June 22 that it is working with Astrazeneca plc’s hematology R&D unit, Acerta Pharma, to develop a combination therapy of its Bcl-2 inhibitor, APG-2575, with Acerta's BTK inhibitor, Calquence (acalabrutinib). The first patient has been dosed in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435987</guid>
      <pubDate>Tue, 23 Jun 2020 13:47:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435987-ascentage-co-develops-bcl-2-and-btk-combination-therapy-for-sllcll-with-astrazeneca</link>
    </item>
    <item>
      <title>Ascentage co-develops Bcl-2 and BTK combination therapy for SLL/CLL with Astrazeneca</title>
      <description>
        <![CDATA[BEIJING – Suzhou, China-based Ascentage Pharma Group Inc. said on Monday that it is working with Astrazeneca plc’s hematology R&D unit, Acerta Pharma, to develop a combination therapy of its Bcl-2 inhibitor, APG-2575, with Acerta's BTK inhibitor, Calquence (acalabrutinib). The first patient has been dosed in the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435952</guid>
      <pubDate>Mon, 22 Jun 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435952-ascentage-co-develops-bcl-2-and-btk-combination-therapy-for-sllcll-with-astrazeneca</link>
    </item>
    <item>
      <title>CSL, University of Queensland partner with CEPI to bring COVID-19 vaccine to the clinic</title>
      <description>
        <![CDATA[PERTH, Australia – Aussie biotech CSL Ltd. and the University of Queensland (UQ) have entered a development agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate development, manufacture and distribution of a COVID-19 vaccine candidate developed by the University of Queensland.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435665</guid>
      <pubDate>Tue, 09 Jun 2020 13:12:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435665-csl-university-of-queensland-partner-with-cepi-to-bring-covid-19-vaccine-to-the-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Jun-2020/Model-of-clamped-vaccine-antigen-6-8.webp?t=1591643208" type="image/png" medium="image" fileSize="121736">
        <media:title type="plain">Model of clamped vaccine antigen</media:title>
        <media:description type="plain">A model of a clamped vaccine antigen.
Credit: D. Watterson, the University of Queensland
</media:description>
      </media:content>
    </item>
    <item>
      <title>Innovent partners with Roche in multibillion-dollar deal targeting bispecifics, cell therapies</title>
      <description>
        <![CDATA[BEIJING – Suzhou, China-based Innovent Biologics Inc. is known in China as one of the first drugmakers to launch a PD-1 monoclonal antibody. Now, the company is moving to expand its product portfolio and enhance efforts in developing bispecific antibodies and cell therapies in a potential multibillion-dollar deal with pharma giant Roche Holding AG.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435671</guid>
      <pubDate>Tue, 09 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435671-innovent-partners-with-roche-in-multibillion-dollar-deal-targeting-bispecifics-cell-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake_global.webp?t=1588276785" type="image/png" medium="image" fileSize="506777">
        <media:title type="plain">Handshake with globe background and digital overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>CSL, University of Queensland partner with CEPI to bring COVID-19 vaccine to the clinic</title>
      <description>
        <![CDATA[PERTH, Australia – Aussie biotech CSL Ltd. and the University of Queensland (UQ) have entered a development agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate  development, manufacture and distribution of a COVID-19 vaccine candidate developed by the University of Queensland.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435631</guid>
      <pubDate>Mon, 08 Jun 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435631-csl-university-of-queensland-partner-with-cepi-to-bring-covid-19-vaccine-to-the-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Jun-2020/Model-of-clamped-vaccine-antigen-6-8.webp?t=1591643208" type="image/png" medium="image" fileSize="121736">
        <media:title type="plain">Model of clamped vaccine antigen</media:title>
        <media:description type="plain">A model of a clamped vaccine antigen.
Credit: D. Watterson, the University of Queensland
</media:description>
      </media:content>
    </item>
    <item>
      <title>Shanghai’s Junshi and Eli Lilly to co-develop antibodies targeting COVID-19</title>
      <description>
        <![CDATA[BEIJING – In one of the latest Sino-foreign collaborations formed to find a cure for the pandemic that has infected 3.5 million people worldwide, Shanghai-based Junshi Biosciences Co. Ltd. and Eli Lilly and Co. have disclosed an agreement to co-develop therapeutic antibodies for preventing and treating COVID-19. Under the terms, Junshi grants Lilly an exclusive license, outside of greater China, to conduct R&D, manufacture and distribute the SARS-CoV-2 JS-016 neutralizing antibodies developed by Junshi.]]>
      </description>
      <guid>http://www.bioworld.com/articles/434857</guid>
      <pubDate>Tue, 05 May 2020 12:20:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/434857-shanghais-junshi-and-eli-lilly-to-co-develop-antibodies-targeting-covid-19</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-therapy-development.webp?t=1589310113" type="image/png" medium="image" fileSize="429893">
        <media:title type="plain">Coronavirus test tube, microscope, gloved hand</media:title>
      </media:content>
    </item>
    <item>
      <title>Abbott partners with Tandem to advance diabetes care solutions</title>
      <description>
        <![CDATA[Abbott Laboratories and Tandem Diabetes Care Inc. said Tuesday that they plan to develop and commercialize a line of integrated diabetes products based on Abbott's glucose sending technology and Tandem's insulin delivery systems. The collaboration comes as the U.S. FDA is encouraging medical device manufacturers to consider the ability to share and use information safely and effectively in the development and design of connected devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430429</guid>
      <pubDate>Wed, 16 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430429-abbott-partners-with-tandem-to-advance-diabetes-care-solutions</link>
    </item>
    <item>
      <title>Australia's Mesoblast inks potential $1B deal with Germany's Grünenthal</title>
      <description>
        <![CDATA[PERTH, Australia – Australian cell therapy developer Mesoblast Ltd. has partnered with Germany's Grünenthal Group to develop and commercialize Mesoblast's allogeneic cell therapy candidate, MPC-06-ID, in a deal that carves out Europe, Latin America and the Caribbean.]]>
      </description>
      <guid>http://www.bioworld.com/articles/429554</guid>
      <pubDate>Wed, 11 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/429554-australias-mesoblast-inks-potential-1b-deal-with-germanys-gr%C3%BCnenthal</link>
    </item>
    <item>
      <title>Sosei Heptares getting $26M up front in potential $1B GPCR deal with Genentech</title>
      <description>
        <![CDATA[LONDON – Sosei Heptares has added Genentech Inc. to the list of partners seeking access to its G protein-coupled receptor (GPCR) expertise, signing a collaboration with a headline value of $1 billion with the Roche Group company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/331708</guid>
      <pubDate>Wed, 17 Jul 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/331708-sosei-heptares-getting-26m-up-front-in-potential-1b-gpcr-deal-with-genentech</link>
    </item>
    <item>
      <title>$3.95B up front + $1.1B equity: Galapagos secures its independence through Gilead R&amp;D alliance</title>
      <description>
        <![CDATA[DUBLIN – In what is a truly transformative deal for each company, Gilead Sciences Inc. and Galapagos NV are entering a 10-year research and development alliance under which Galapagos is getting $3.95 billion up front in hard cash plus another $1.1 billion in equity, in return for which Gilead will essentially have an option to ex-European rights on everything emanating from the Belgium firm's clinical and preclinical pipeline. That includes six clinical-stage programs, another 20 in preclinical research and whatever else Galapagos may bring forward – or bring in through its own business development efforts – over the term of the agreement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/359550</guid>
      <pubDate>Tue, 16 Jul 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/359550-395b-up-front-11b-equity-galapagos-secures-its-independence-through-gilead-rd-alliance</link>
    </item>
  </channel>
</rss>
